Design, synthesis and bioevaluation of antitubulin agents carrying diaryl-5,5-fused-heterocycle scaffold
作者:Qile Xu、Maolin Sun、Zhaoshi Bai、Yueting Wang、Yue Wu、Haiqiu Tian、Daiying Zuo、Qi Guan、Kai Bao、Yingliang Wu、Weige Zhang
DOI:10.1016/j.ejmech.2017.05.065
日期:2017.10
A series of 3,6-diaryl-1H-pyrazolo[5,1-c][1,2,4]triazoles (I) and 3,6-diaryl-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles (II) as antitubulin agents were designed, synthesized and bioevaluated. Compounds (II) 4a, 4d, 4f, 4j, 4l and 4n showed potent antiproliferative activity at sub-micromolar or nanomolar concentrations against SGC-7901, A549 and HT-1080 cell lines, indicating that the bioisosteric replacement
一系列3,6-二芳基-1 H-吡唑并[5,1-c] [1,2,4]三唑(I)和3,6-二芳基-[1,2,4]三唑并[3,4 -b] [1,3,4]噻二唑(II)作为抗微管蛋白药物的设计,合成和生物评价。化合物(II)4a,4d,4f,4j,4l和4n在亚微摩尔或纳摩尔浓度下对SGC-7901,A549和HT-1080细胞系表现出有效的抗增殖活性,表明羰基和B的生物立体取代5,5-融合杂环支架将SMART和ABI环成功地保持了有效的抗增殖活性。化合物4f对三种癌细胞系表现出最优异的抗增殖活性(IC 50 = 0.022–0.029μM)。与其强大的抗增殖活性一致,4f还显示出出色的抗微管蛋白活性(IC 50 = 0.77μM)。此外,化合物4f可以显着影响细胞形态和微管网络,而细胞周期研究表明4f可以显着诱导SGC-7901细胞停滞在G2 / M期。此外,分子对接研究支持了生物学测定数据,并暗示4f可能是潜在的抗微管蛋白药物。